The Cytokeratin-7 (CK-7) by IHC test is an immunohistochemistry procedure used to detect CK-7 protein expression in tissue samples. CK-7 is a cytoskeletal marker commonly expressed in epithelial cells of the lung, breast, ovary, and urinary tract. This test is performed to help pathologists determine the origin of tumors, differentiate between cancer types, and guide treatment decisions. It is particularly useful in distinguishing CK-7 positive carcinomas from CK-7 negative malignancies, ensuring accurate diagnosis and management.
Yes, CK-7 expression patterns help differentiate primary tumors from metastases, especially in lung, breast, and ovarian cancers.
Most breast carcinomas are CK-7 positive, but exceptions exist, so other markers may be used alongside CK-7 for confirmation.
Yes, CK-7 positivity supports diagnosis of adenocarcinoma of the lung, distinguishing it from squamous cell carcinoma which is usually CK-7 negative.
No, CK-7 is used in combination with other markers like CK-20, ER, PR, and GATA-3 for accurate tumor classification.
Colorectal carcinoma and hepatocellular carcinoma are usually CK-7 negative, helping distinguish them from CK-7 positive tumors.
Expression may vary, but CK-7 positivity is generally consistent across tumor grades in CK-7 associated cancers.
Yes, CK-7 positivity supports diagnosis of ovarian carcinoma, especially serous and endometrioid subtypes.
...
Didn't recieved OTP Yet? Resend OTP